Treating multiple sclerosis with fingolimod or intramuscular interferon

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 11, 2010, Pages 1957-1960

  Pozzilli, Carlo ^a   Prosperini, Luca ^a   Borriello, Giovanna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Clinical trials in multiple sclerosis; Fingolimod; Oral therapies in multiple sclerosis; TRANSFORMS

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD;

ARTICLE; ATRIOVENTRICULAR BLOCK; BASAL CELL CARCINOMA; BRADYCARDIA; BREAST CANCER; CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; HERPES SIMPLEX; HUMAN; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MELANOMA; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; RELAPSE; REMISSION; RETINA MACULA EDEMA; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN CANCER;

EID: 77954770072     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.484422     Document Type: Article

References (11)

1. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415
2. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-1140
3. O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009;72:73-79
4. Montalban X, O'Connor P, Antel G, et al. Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four-year results from a phase II extension. Neurology 2009;72(Suppl 3):A313
5. Kappos L, Radue EW, O'Connor P, et al.; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
6. Gasperini C, Cefaro LA, Borriello G, et al. Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs 2008;13:465-477
7. Mikol DD, Barkhof F, Chang P, et al.; REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-914
8. O'Connor P, Filippi M, Arnason B, et al.; BEYOND Study Group. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-897
9. Herr DR, Chun J. Effects of LPA and S1P on the nervous system and implications for their involvement in disease. Curr Drug Targets 2007;8:155-167
10. Miron VE, Jung CG, Kim HJ, et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008;63:61-71
11. Storch M, Rausch M, Hiestand P, et al. FTY720 not only prevents EAE onset, as assessed by MRI, but also reverses established neurological deficits and extensive demyelination. Presented at the 22nd ECTRIMS congress. Mult Scler 2006;12(Suppl 2):P188